Barinthus Biotherapeutics (BRNS) Operating Margin (2020 - 2024)

Barinthus Biotherapeutics has reported Operating Margin for 5 years, with the latest figure at 62.66% in Q3 2024.

• For the quarter ending Q3 2024, Operating Margin changed N/A year-over-year to 62.66%; the trailing twelve-month figure through Dec 2025 stood at 471.34% (down 1727.0% YoY), and the FY2024 full-year result was 454.07%, up 1000902.0% from the prior year.
• Operating Margin for Q3 2024 stood at 62.66%, up from 7885.33% in the prior quarter.
• The five-year high for Operating Margin was 1666800.0% in Q4 2021, with the low at 48128.57% in Q2 2021.
• Historically, Operating Margin has averaged 104644.19% across 5 years, with a median of 659.43% in 2020.
• Annual changes were most pronounced in 2021 — Operating Margin surged 166952119 bps — and 2022, when it tumbled 166718862 bps.
• Barinthus Biotherapeutics' Operating Margin stood at 2721.19% in 2020, then soared by 61353 bps to 1666800.0% in 2021, then plunged by 100 bps to 388.62% in 2022, then tumbled by 1929 bps to 7885.33% in 2023, then surged by 99 bps to 62.66% in 2024.
• The last three Operating Margin figures came in at 62.66% (Q3 2024), 7885.33% (Q2 2023), and 4590.6% (Q1 2023), per Business Quant data.